# US 2025/0152944 A1 · Systems and methods to titrate scs dosing through autonomic measures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152944 A1
- Document ID: US20250152944A1
- Status: Published application
- Kind: A1
- Application number: 18/945,383
- Filed: 2024-11-12
- Published: 2025-05-15
- Earliest claimed: 2023-11-13
- Assignees: Boston Scientific Neuromodulation Corporation
- Applicants: Boston Scientific Neuromodulation Corporation
- Inventors: Lisa Denise Moore; Tianhe Zhang; Que T. Doan
- Web page: https://patentgrep.com/patent/US20250152944A1

## CPC

- A61N 1/36139: {with automatic adjustment}
- A61B 5/1116: {Determining posture transitions}
- A61B 5/4035: {Evaluating the autonomic nervous system}
- A61B 5/4836: {Diagnosis combined with treatment in closed-loop systems or methods (A61B5/0036 takes precedence)}
- A61N 1/36062: {Spinal stimulation}
- A61N 1/36071: {Pain}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Methods and systems for delivering a therapy and observing one or more metrics of autonomic function. Spinal cord stimulation may be initiated, and patient response monitored using one or more metrics of autonomic function, including heart rate, heart rate variability, or other markers. Therapy intensity may be increased or decreased, or therapy may be changed to use a different program, or therapy may be ceased, depending on changes in the observed metrics of autonomic function.

## Claims

### Claim 1

A method of treating a patient having an implantable medical device system including a lead adapted for placement in the spinal column of a patient and a housing containing each of a sensing circuitry configured to sense a metric of the patient's autonomic function, and a stimulation circuitry configured to issue pulses via the lead; the method comprising:
issuing pulses to the patient in accordance with a first treatment program;
determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation; and
in response to a determination that the metric of the patient's autonomic function indicates a risk of overregulation, reducing the risk of overregulation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by tracking a trend the metric.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
detecting, using the sensing circuitry, heart beats of the patient;
determining, from the detected heart beats, a cardiac rate of the patient; and
comparing the cardiac rate or a trend of the cardiac rate to a threshold.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
detecting, using the sensing circuitry, heart beats of the patient;
determining, from the detected heart beats, a heart rate variability of the patient; and
comparing the heart rate variability or a trend of the heart rate variability to a threshold.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
detecting, using the sensing circuitry, a respiration rate of the patient;
comparing the respiration rate, or a trend of the respiration rate, to a threshold.

### Claim 6 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
detecting, using the sensing circuitry, heart beats of the patient;
analyzing the heart beats of the patient to yield a first estimate of the patient's autonomic state;
obtaining data from a second device to yield a second estimate of the patient's autonomic state, wherein the second device provides an indication of blood pressure.

### Claim 7 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
detecting, using the sensing circuitry, heart beats of the patient;
analyzing the heart beats of the patient to yield a first estimate of the patient's autonomic state;
obtaining data from a second device to yield a second estimate of the patient's autonomic state, wherein the second device provides an indication of galvanic skin resistance of the patient.

### Claim 8 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
determining a first autonomic function marker and a second autonomic function marker each selected from heart rate, heart rate variability, blood pressure, respiration rate, galvanic skin response, bladder, bowel or sexual function, posture and myopotentials; and
using the first autonomic function marker and the second autonomic function marker to estimate the metric.

### Claim 9 (depends on 1)

The method of claim 1, wherein the step of determining, from the sensing circuitry, whether the metric of the patient's autonomic function indicates a risk of overregulation, is performed by:
identifying a first marker of autonomic function of the patient,
obtaining an activity signal from the patient indicating a level of intentional activity by the patient, and
determining an effect on the first marker caused by intentional activity of the patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the step of obtaining an activity signal is performed by using an accelerometer in the sensing circuitry.

### Claim 11 (depends on 9)

The method of claim 9, wherein the step of obtaining an activity signal is performed by monitoring a component of the electrospinogram.

### Claim 12 (depends on 1)

The method of claim 1, wherein the step of reducing the risk of overregulation is performed by reducing one or more of an intensity, a repetition rate, a pulse width, or an amplitude of the pulses delivered to the patient.

### Claim 13 (depends on 1)

The method of claim 1, wherein the step of reducing the risk of overregulation is performed by ceasing to issue pulses to the patient in accordance with the first treatment program.

### Claim 14 (depends on 13)

The method of claim 13, further comprising, after ceasing to issue pulses to the patient in accordance with the first treatment program, issuing pulses to the patient in accordance with a second treatment program.

### Claim 15 (depends on 1)

The method of claim 1, wherein the implantable medical device system further includes a patient remote control external of the patient having a user interface and communication circuitry for communicating with the pulse generator, wherein the step of reducing the risk of overregulation is performed by communicating to the remote control to present a query to the patient regarding stimulation the patient is receiving.

### Claim 16 (depends on 1)

The method of claim 1, wherein the step of reducing the risk of overregulation is performed by issuing a communication with an alert that the patient is at risk of overregulation.

### Claim 17

A method of treating a patient using a spinal cord stimulator, comprising:
generating a mapping of autonomic status of the patient using a first metric and a second metric, the mapping including a first region for a stressed status, and a second region for a relaxed status;
initiating therapy using a first therapy program;
confirming, by tracking the first metric and the second metric, that the patient's autonomic status has shifted from the first region to the second region in response to initiating therapy using the first therapy program;
monitoring the patient's autonomic status in the second region as therapy continues using the first therapy program;
determining that the patient's autonomic status has left the second region;
in response to the determining that the patient's autonomic status has left the second region, determining that the patient is overregulated.

### Claim 18 (depends on 17)

The method of claim 17, further comprising, in response to determining that the patient is overregulated, reducing one or more of an intensity, a repetition rate, a pulse width, or an amplitude of pulses delivered to the patient in the first therapy program.

### Claim 19 (depends on 17)

The method of claim 17, further comprising, in response to determining that the patient is overregulated, terminating therapy using the first therapy program, and initiating therapy using a second therapy program.

### Claim 20 (depends on 17)

The method of claim 17, wherein the first metric is heart rate, and the second metric is heart rate variability.
